Xilio Therapeutics, Inc. (XLO)

Every figure this model derived for XLO, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 670,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 136,040,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 145,468,000 AssetsCurrent 2026-06-30
current liabilities 34,198,000 LiabilitiesCurrent 2026-06-30
equity 72,264,000 StockholdersEquity 2026-06-30
ocf -60,598,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 64,092,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 7,862,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up XLO on one particular measure came for.

RatioValue
cash operating margin-34.59
current ratio12.55
current ratio reported4.25
deferred revenue growth-46.54
dilution pct118.81
fcf margin-95.59
operating margin-48.94
owner earnings margin-107.86
revenue growth327.25
revenue growth per share95.26
rule of 40278.31
sbc pct revenue12.27

What to be careful about

What this model itself distrusts about XLO's figures. Written by the derivation as it ran, not added afterwards.